Background: Valsartan is a pharmaceutical agent that belongs to the class of medications known as angiotensin II receptor blockers (ARBs). It is widely prescribed for the treatment of hypertension (high blood pressure) and heart failure. Valsartan acts by selectively blocking the binding of angiotensin II to its receptors, thereby inhibiting its vasoconstrictive and aldosterone-secreting effects. Aim: This study aims to assess the pharmacological effects of Valsartan as an anti-hypertensive agent and explore its potential role as an anti-inflammatory agent in patients with stable hemodynamic circumstances. Methods: A monocentric, non-profit, prospective pharmacological interventional pilot investigation was carried out. We prospectively included consecutive patients with stable hemodynamic circumstances who were qualified for S/V treatment in accordance with the Guidelines after obtaining their informed written consent for the anonymous collection and dissemination of data. Between January and March 2023, all patients at Imam Hussain Educational Medical City in Karbala, Iraq, were monitored. Conclusion: The association between interleukin 6 (IL6) and other variables, such as age and BMI, did not show significant correlations in this study. This suggests that IL6 levels may not be strongly influenced by age or BMI in the study population. the study revealed a significant association between the use of valsartan and IL6 levels. This finding suggests that valsartan may have an impact on IL6 levels in the study population.